Antibody-drug conjugate shows promise in treating ovarian and endometrial cancers

New cancer studies suggest benefits from adding immunotherapy to standard treatments for early-stage endometrial and cervical cancers. Further, a novel antibody drug showed promising outcomes for patients with ovarian and endometrial cancers. A phase 3 study showed pembrolizumab plus chemoradiotherapy significantly improved overall survival in high-risk locally advanced cervical cancer. However, the therapy did not improve disease-free survival in high-risk endometrial cancer patients but showed benefits for those with deficient mismatch repair tumors.